Morbidity and quality of life following cytoreduction and HIPEC.
Deraco
M
M
Department of Surgery, National Cancer Institute, Milano, Italy. marcello.deraco@istitutotumori.mi.it
Baratti
D
D
Kusamura
S
S
D002277:Carcinoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D007410:Intestinal Diseases / Q000175:diagnosis; D008297:Male; D019060:Minimally Invasive Surgical Procedures; D009017:Morbidity; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011183:Postoperative Complications; D011788:Quality of Life; D016019:Survival Analysis